Patient perspectives on window of opportunity clinical trials in early-stage breast cancer
- PMID: 35538268
- PMCID: PMC9090598
- DOI: 10.1007/s10549-022-06611-6
Patient perspectives on window of opportunity clinical trials in early-stage breast cancer
Abstract
Purpose: Window of opportunity trials (WOT) are increasingly common in oncology research. In WOT participants receive a drug between diagnosis and anti-cancer treatment, usually for the purpose of investigating that drugs effect on cancer biology. This qualitative study aimed to understand patient perspectives on WOT.
Methods: We recruited adults diagnosed with early-stage breast cancer awaiting definitive therapy at a single-academic medical center to participate in semi-structured interviews. Thematic and content analyses were performed to identify attitudes and factors that would influence decisions about WOT participation.
Results: We interviewed 25 women diagnosed with early-stage breast cancer. The most common positive attitudes toward trial participation were a desire to contribute to research and a hope for personal benefit, while the most common concerns were the potential for side effects and how they might impact fitness for planned treatment. Participants indicated family would be an important normative factor in decision-making and, during the COVID-19 pandemic, deemed the absence of family members during clinic visits a barrier to enrollment. Factors that could hinder participation included delay in standard treatment and the requirement for additional visits or procedures. Ultimately, most interviewees stated they would participate in a WOT if offered (N = 17/25).
Conclusion: In this qualitative study, interviewees weighed altruism and hypothetical personal benefit against the possibility of side effect from a WOT. In-person family presence during trial discussion, challenging during COVID-19, was important for many. Our results may inform trial design and communication approaches in future window of opportunity efforts.
Keywords: Breast cancer; Clinical trials; Patient perspectives; Window of opportunity.
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
Conflict of interest statement
DAP, LK, SB, DH, VL, MK, IW, and GWS have no conflicts of interest to disclose. CC is a scientific advisor and consultant for Genentech, Grail, NanoString, DeepCell, Ravel, and ResistanceBio and has stock at Grail, Ravel, and DeepCell. MP is a consultant for Celgene and an advisor for Pacific Business Group. JLC has received research funding from QED Therapeutics and eFFECTOR Therapeutics to her institution.
Figures
Similar articles
-
Attitudes and barriers to participation in window-of-opportunity trials reported by White and Asian/Asian British ethnicity patients who have undergone treatment for endometrial cancer.Trials. 2023 Nov 25;24(1):754. doi: 10.1186/s13063-023-07572-x. Trials. 2023. PMID: 38007461 Free PMC article.
-
Perspectives on Oncology-Specific Language During the Coronavirus Disease 2019 Pandemic: A Qualitative Study.JAMA Oncol. 2020 Sep 1;6(9):1424-1428. doi: 10.1001/jamaoncol.2020.2980. JAMA Oncol. 2020. PMID: 32761102 Free PMC article.
-
Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates.BMC Cancer. 2022 Feb 4;22(1):141. doi: 10.1186/s12885-022-09189-w. BMC Cancer. 2022. PMID: 35120494 Free PMC article.
-
Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis.Cochrane Database Syst Rev. 2023 Sep 1;9(9):MR000065. doi: 10.1002/14651858.MR000065.pub2. Cochrane Database Syst Rev. 2023. PMID: 37655964 Free PMC article. Review.
-
What matters in clinical trial decision-making: a systematic review of interviews exploring cancer patients' experiences.Scand J Caring Sci. 2019 Jun;33(2):266-278. doi: 10.1111/scs.12637. Epub 2019 Feb 8. Scand J Caring Sci. 2019. PMID: 30735263
Cited by
-
Barriers to recruitment in a pre-surgical trial for ductal carcinoma in situ: an exploratory qualitative study of at-risk women, survivors, and providers.Breast Cancer Res Treat. 2025 Aug;213(1):33-42. doi: 10.1007/s10549-025-07742-2. Epub 2025 Jul 3. Breast Cancer Res Treat. 2025. PMID: 40610815 Free PMC article.
References
-
- Caswell-Jin JL, Lorenz C, Curtis C. Molecular heterogeneity and evolution in breast cancer. Ann Rev Cancer Biol. 2021;5(1):79–94. doi: 10.1146/annurev-cancerbio-060220-014137. - DOI
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical